2017
Comparison of Accuracy of One-Use Methods for Calculating Fractional Flow Reserve by Intravascular Optical Coherence Tomography to That Determined by the Pressure-Wire Method
Jang S, Ahn J, Kim B, Gu J, Sung H, Park S, Oh W. Comparison of Accuracy of One-Use Methods for Calculating Fractional Flow Reserve by Intravascular Optical Coherence Tomography to That Determined by the Pressure-Wire Method. The American Journal Of Cardiology 2017, 120: 1920-1925. PMID: 29050684, DOI: 10.1016/j.amjcard.2017.08.010.Peer-Reviewed Original Research
2016
Characterization of lipid-rich plaques using spectroscopic optical coherence tomography
Nam H, Song J, Jang S, Lee J, Oh W, Kim J, Yoo H. Characterization of lipid-rich plaques using spectroscopic optical coherence tomography. Journal Of Biomedical Optics 2016, 21: 075004-075004. PMID: 27391375, DOI: 10.1117/1.jbo.21.7.075004.Peer-Reviewed Original ResearchIntracoronary dual-modal optical coherence tomography-near-infrared fluorescence structural–molecular imaging with a clinical dose of indocyanine green for the assessment of high-risk plaques and stent-associated inflammation in a beating coronary artery
Kim S, Lee M, Kim T, Song J, Nam H, Cho H, Jang S, Ryu J, Oh D, Gweon D, Park S, Park K, Oh W, Yoo H, Kim J. Intracoronary dual-modal optical coherence tomography-near-infrared fluorescence structural–molecular imaging with a clinical dose of indocyanine green for the assessment of high-risk plaques and stent-associated inflammation in a beating coronary artery. European Heart Journal 2016, 37: 2833-2844. PMID: 26787442, DOI: 10.1093/eurheartj/ehv726.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsHumansIndocyanine GreenInflammationMolecular ImagingStentsSwineTomography, Optical CoherenceConceptsHigh-risk plaquesCoronary arteryOptical coherence tomographyIndocyanine greenClinical doseCoherence tomographySwine coronary arteriesLipid-rich plaquesNIRF signalStent-associated complicationsSaline-injected controlsStrong NIRF signalPlaque inflammationPlaque disruptionDES deploymentCoronary imagingFibrous plaquesHuman plaquesInflammationICG uptakeYucatan minipigsPlaquesArteryHistological validationStent struts
2013
Differential long‐term outcomes of zotarolimus‐eluting stents compared with sirolimus‐eluting and paclitaxel‐eluting stents in diabetic and nondiabetic patients: Two‐year subgroup analysis of the ZEST randomized trial
Jang S, Park D, Kim W, Kim Y, Yun S, Kang S, Lee S, Lee C, Park S, Park S. Differential long‐term outcomes of zotarolimus‐eluting stents compared with sirolimus‐eluting and paclitaxel‐eluting stents in diabetic and nondiabetic patients: Two‐year subgroup analysis of the ZEST randomized trial. Catheterization And Cardiovascular Interventions 2013, 81: 1106-1114. PMID: 22899589, DOI: 10.1002/ccd.24603.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary ThrombosisDiabetes MellitusDrug-Eluting StentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProspective StudiesProsthesis DesignRepublic of KoreaRisk AssessmentRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsZotarolimus-eluting stentsSirolimus-eluting stentsNondiabetic patientsDiabetic statusDiabetic patientsStent typeIschemia-driven target vessel revascularizationDifferential long-term outcomesLower ratesAdverse cardiac eventsComposite of deathTarget vessel revascularizationLong-term outcomesDifferential treatment effectsSimilar ratesAngiographic characteristicsIschemic complicationsCardiac eventsDiabetes mellitusPrimary outcomeMACE occurrenceStent groupMyocardial infarction
2011
Fatal Rhabdomyolysis in a Patient with Liver Cirrhosis after Switching from Simvastatin to Fluvastatin
Baek S, Jang S, Park S, Ok T, Leem J, Lee H, Park S, Kim T. Fatal Rhabdomyolysis in a Patient with Liver Cirrhosis after Switching from Simvastatin to Fluvastatin. Journal Of Korean Medical Science 2011, 26: 1634-1637. PMID: 22148003, PMCID: PMC3230026, DOI: 10.3346/jkms.2011.26.12.1634.Peer-Reviewed Original ResearchConceptsFatal rhabdomyolysisLiver cirrhosisContinuous renal replacement therapyAcute renal failureRenal replacement therapyCoronary artery diseaseHMG-CoA reductase inhibitorsSerum creatine kinaseAsymptomatic elevationIntravenous furosemideRenal failureUrine alkalizationArtery diseaseHepatic failureReplacement therapyMassive hydrationRhabdomyolysisPatientsCirrhosisReductase inhibitorsCreatine kinaseAdverse effectsSimvastatinFluvastatinCandesartan